WAM
RNTX

Warberg Asset Management’s Rein Therapeutics RNTX Stock Holding History

Warberg Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,000
Closed -$12.6K – 229
2025
Q3 		$12.6K Buy
+11,000
New +$14K ﹤0.01% 166
2024
Q4 		– Sell
-10,000
Closed -$35.4K – 239
2024
Q3 		$35.4K Sell
10,000
-21,354
-68% -$57.1K 0.01% 146
2024
Q2 		$86.2K Buy
+31,354
New +$129K 0.01% 138

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Warberg Asset Management's RNTX Position: Q4 2025 in Review

Warberg Asset Management sold out of Rein Therapeutics (RNTX) in Q4 2025, closing a stake of 11,000 shares — an estimated $12.6K sold.

Warberg Asset Management first reported a position in RNTX in Q2 2024 and held it in 3 quarters. The position peaked at $86.2K in Q2 2024. 48 funds tracked by Wall St. Rank hold RNTX as of Q4 2025.

  • Warberg Asset Management reported no remaining Rein Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Warberg Asset Management sold 11,000 Rein Therapeutics shares in Q4 2025, an estimated $12.6K.
  • Warberg Asset Management first reported a position in Rein Therapeutics in Q2 2024 and held it in 3 quarters.
  • Warberg Asset Management's Rein Therapeutics position peaked at $86.2K in Q2 2024.
  • 48 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2025.

Based on Warberg Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.